Latest News
From the Journals
Gene therapy found promising in patients with hemophilia B
The treatment prevented bleeding and virtually eliminated the need for exogenous factors.
Feature
ABIM to allow do-overs for all subspecialties with Knowledge Check-In
The option had been available only for internal medicine and nephrology.
News
Anti-BCMA CAR T-cell therapy being fast tracked at FDA
The CAR T-cell therapy bb2121 was granted breakthrough therapy designation by the Food and Drug Administration, speeding its review process.
Feature
Medicare pay cut may loom in wake of tax bill passage
Could revoking the individual mandate trigger lower Medicare reimbursement?
From the Journals
Mammography screening’s benefits for breast cancer mortality questioned
A Dutch mammography screening program worsens overdiagnosis without significantly reducing mortality.
Conference Coverage
Ultrathin bronchoscopy plus radial EBUS unreliable at making diagnoses
Researchers made diagnoses for fewer than half of patients who had their nodules evaluated using ultrathin bronchoscopy plus radial EBUS.
From the Journals
ASCO platelet transfusion guidelines updated
Five key recommendations have been updated since the guidelines were first published in 2001.
From the Journals
ASCO larynx-preservation guidelines reflect important practice changes
Larynx-preserving techniques do not compromise survival in patients with early-stage laryngeal cancers.
Conference Coverage
E-health app helps weight loss, QOL for African American breast cancer survivors
MONTREAL – Overall, but not cancer-related, quality of life improved significantly for participants.
Conference Coverage
First-in-class glutaminase inhibitor combats anti-PD-1/PD-L1 resistance
NATIONAL HARBOR, MD. – Responses in melanoma patients who were progressing on nivolumab at study entry and who were refractory to multiple prior...
From the Journals
Refractory FGFR-altered cholangiocarcinoma responds to FGFR kinase inhibitor
A median progression-free survival of 5.8 months is encouraging in patients with this aggressive cancer, and this targeted therapy warrants...